Literature DB >> 9364574

Platelet prostanoid receptors.

R A Armstrong1.   

Abstract

Prostaglandins (PGs) and thromboxanes are important modulators of platelet activation, and there is strong evidence to support the existence of distinct thromboxane, prostacyclin, PGD2 and PGE2 receptors on the platelet plasma membrane. In this review, each of these platelet prostanoid receptors is discussed in detail, with respect to their receptor pharmacology, molecular biology and signal transduction, and as to any therapeutic implications of the development of specific agonists and/or antagonists. In addition, it considers the possibility that there are separate vascular receptors for 8-epi PGF2 alpha, which are not present on the platelet.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 9364574     DOI： 10.1016/s0163-7258(96)00103-9

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN： 0163-7258            Impact factor:   12.310


  17 in total

1.  Characterization of the effects of isoprostanes on platelet aggregation in human whole blood.

Authors:  J H Cranshaw; T W Evans; J A Mitchell
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

2.  Biased suppression of TP homodimerization and signaling through disruption of a TM GxxxGxxxL helical interaction motif.

Authors:  Alexander J Frey; Salam Ibrahim; Scott Gleim; John Hwa; Emer M Smyth
Journal:  J Lipid Res       Date:  2013-03-14       Impact factor: 5.922

3.  Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation.

Authors:  J E Fabre; M Nguyen; K Athirakul; K Coggins; J D McNeish; S Austin; L K Parise; G A FitzGerald; T M Coffman; B H Koller
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

Review 4.  Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy.

Authors:  J A Mitchell; T D Warner
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

5.  Thromboxane and the thromboxane receptor in cardiovascular disease.

Authors:  Emer M Smyth
Journal:  Clin Lipidol       Date:  2010-04-01

6.  Differential inhibition of tumour cell-induced platelet aggregation by the nicotinate aspirin prodrug (ST0702) and aspirin.

Authors:  Carlos Medina; Shona Harmon; Iwona Inkielewicz; Maria Jose Santos-Martinez; Michael Jones; Paula Cantwell; Despina Bazou; Mark Ledwidge; Marek W Radomski; John F Gilmer
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 7.  Platelets in liver and renal disease.

Authors:  Michele P Lambert
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

8.  Effect of the statin atorvastatin on intracellular signalling by the prostacyclin receptor in vitro and in vivo.

Authors:  Sarah J O'Meara; B Therese Kinsella
Journal:  Br J Pharmacol       Date:  2004-08-23       Impact factor: 8.739

9.  EP1- and FP-mediated cross-desensitization of the alpha (alpha) and beta (beta) isoforms of the human thromboxane A2 receptor.

Authors:  Leanne P Kelley-Hickie; B Therese Kinsella
Journal:  Br J Pharmacol       Date:  2004-04-20       Impact factor: 8.739

10.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.